8.5
90.3 %
92.7 %
Indicators in the Citation impact, Journal impact and Co‑publishing tabs are based on Web of Science publications only. Corresponding Scopus indicators can be found under the Scopus tab.
Overall Web of Science coverage for peer reviewed publications in this unit is good, 90.3%.
Note that the coverage numbers for Web of Science and Scopus apply to publications in the KTH bibliometric database Bibmet. If a WoS-id or Scoupus-id from DiVA can not be matched in Bibmet, it does not count as covered.
The bibliometric indicators referred are based on publications registered in DiVA. Only publications from currently employed researchers at KTH are included. The rolling nature of this report means that it provides more of a current overview and less of a historic stable trend, since it excludes publications written by researchers that are no longer affiliated to KTH, but have been at some point in time.
Indicators in the Citation impact, Journal impact and Co‑publishing tabs are based on Web of Science publications only. Corresponding Scopus indicators can be found under the Scopus tab.
Publication data is available only after login.
| DiVA publication type | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | Publications | WoS coverage | Scopus coverage |
|---|---|---|---|---|---|---|---|---|---|---|
| Article, peer review | 2.4 | 3 | 4.7 | 1.8 | 5.0 | 5.1 | 4.7 | 26.7 | 92.1% | 0.9 |
| Article, other | 0.3 | NA | 1.1 | 0.2 | 0.8 | 1.1 | 0.5 | 4.1 | 100.0% | 0.0 |
| Conference paper, peer review | NA | NA | NA | NA | 0.4 | NA | 0.6 | 1.0 | 40.2% | 1.0 |
| Conference paper, other | 0.7 | NA | 0.2 | 0.9 | 0.2 | NA | 0.9 | 2.9 | 0.0% | 0.2 |
| Chapter in book | 0.3 | NA | NA | NA | 0.8 | NA | 0.8 | 1.9 | 0.0% | 0.6 |
| Doctoral thesis | NA | NA | 1.0 | NA | 2.0 | NA | 1.0 | 4.0 | 0.0% | 0.0 |
| Patent | NA | 1 | 0.5 | 1.0 | NA | 0.5 | NA | 3.0 | 0.0% | 0.0 |
| DiVA publication type | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | Publications | WoS coverage | Scopus coverage |
|---|---|---|---|---|---|---|---|---|---|---|
| Article, peer review | 13 | 15 | 13 | 7 | 14 | 17 | 19 | 98 | 94.9% | 1 |
| Article, other | 2 | NA | 2 | 1 | 3 | 4 | 2 | 14 | 100.0% | 0 |
| Conference paper, peer review | NA | NA | NA | NA | 1 | NA | 2 | 3 | 33.3% | 1 |
| Conference paper, other | 1 | NA | 1 | 2 | 1 | NA | 2 | 7 | 0.0% | 0 |
| Chapter in book | 1 | NA | NA | NA | 2 | NA | 1 | 4 | 0.0% | 1 |
| Doctoral thesis | NA | NA | 1 | NA | 2 | NA | 1 | 4 | 0.0% | 0 |
| Patent | NA | 1 | 1 | 1 | NA | 1 | NA | 4 | 0.0% | 0 |
| Publication Year | Publications | Total Citations | Average Citations | Uncited publications | Share uncited |
|---|---|---|---|---|---|
| 2014 | 1.4 | 7.9 | 5.5 | 0.3 | 23.3% |
| 2015 | 2.8 | 103.2 | 36.8 | 0.0 | 0.0% |
| 2016 | 3.5 | 21.9 | 6.3 | 0.3 | 9.6% |
| 2017 | 1.8 | 55.0 | 30.5 | 0.2 | 13.9% |
| 2018 | 4.9 | 23.0 | 4.7 | 0.4 | 8.1% |
| Total | 14.4 | 211.0 | 14.6 | 1.3 | 9.1% |
| Publication years | Publications | Average Cf | Top 10% publications | Share Top 10% |
|---|---|---|---|---|
| 2014-2016 | 7.7 | 3.42 | 0.5 | 6.4% |
| 2015-2017 | 8.1 | 3.92 | 0.9 | 10.6% |
| 2016-2018 | 9.8 | 1.39 | 0.6 | 6.3% |
| 2017-2019 | 11.4 | 1.23 | 0.8 | 6.7% |
| Total | 19.1 | 2.11 | 1.3 | 6.6% |
This table is based on Web of Science publication types Article, Proceedings paper, Review, Letter and Editorial.
Rows are based on at least 7 (full counted) publications with poor Web of Science coverage (at least 58.8%).
(DiVA publication types Article, peer review and Conference paper, peer review)
Indicators based on < 50 publications are considered unreliable
This table is based on Web of Science publication types Article and Review.
Rows are based on at least 33 (full counted) publications with good Web of Science coverage (at least 90.1%).
(DiVA publication type Article, peer review)
Indicators based on < 50 publications are considered unreliable
| Publication years | Publications | Average Journal Cf | Publications in Top 20% journals | Share Top 20% journals |
|---|---|---|---|---|
| 2014-2016 | 7.7 | 1.34 | 2.7 | 34.8% |
| 2015-2017 | 8.1 | 1.71 | 4.0 | 49.1% |
| 2016-2018 | 9.8 | 2.00 | 6.0 | 61.7% |
| 2017-2019 | 11.4 | 1.92 | 7.2 | 63.3% |
| 2018-2020 | 13.7 | 1.67 | 7.3 | 53.5% |
| Total | 23.2 | 1.64 | 11.6 | 49.9% |
This table is based on Web of Science publication types Article and Review.
Rows are based on at least 33 (full counted) publications with good Web of Science coverage (at least 90.1%).
(DiVA publication type Article, peer review)
Indicators based on < 50 publications are considered unreliable
| Publication years | Publications | Swedish non-university co-publications | Share Swedish non-university | International co-publications | Share international |
|---|---|---|---|---|---|
| 2014-2016 | 35 | 5 | 14.3% | 18 | 51.4% |
| 2015-2017 | 31 | 6 | 19.4% | 17 | 54.8% |
| 2016-2018 | 31 | 5 | 16.1% | 14 | 45.2% |
| 2017-2019 | 37 | 8 | 21.6% | 19 | 51.4% |
| 2018-2020 | 47 | 11 | 23.4% | 24 | 51.1% |
| Total | 89 | 19 | 21.3% | 46 | 51.7% |
This table is based on Web of Science publication types Article and Review.
Rows are based on at least 31 (full counted) publications with good Web of Science coverage (at least 94%).
(DiVA publication type Article, peer review)
Indicators based on < 50 publications are considered unreliable
| Country | Publications | 1-10 auth | 11-50 auth | 51-200 auth | Over 200 auth | Publications (frac) |
|---|---|---|---|---|---|---|
| Denmark | 15 | 7 | 7 | 1 | 0 | 3.1 |
| United Kingdom | 10 | 3 | 7 | 0 | 0 | 2.0 |
| India | 8 | 4 | 4 | 0 | 0 | 1.4 |
| Russian Federation | 5 | 1 | 4 | 0 | 0 | 1.2 |
| United States | 9 | 3 | 5 | 1 | 0 | 1.2 |
| Germany | 4 | 2 | 2 | 0 | 0 | 0.8 |
| Netherlands | 4 | 1 | 3 | 0 | 0 | 0.7 |
| Belgium | 3 | 3 | 0 | 0 | 0 | 0.7 |
| Canada | 2 | 2 | 0 | 0 | 0 | 0.5 |
| Norway | 6 | 1 | 5 | 0 | 0 | 0.5 |
| Singapore | 1 | 1 | 0 | 0 | 0 | 0.4 |
| Austria | 1 | 0 | 1 | 0 | 0 | 0.4 |
| Spain | 5 | 2 | 3 | 0 | 0 | 0.4 |
| Australia | 1 | 1 | 0 | 0 | 0 | 0.3 |
| Korea, Republic of | 3 | 1 | 2 | 0 | 0 | 0.3 |
| France | 1 | 1 | 0 | 0 | 0 | 0.3 |
| Japan | 3 | 1 | 2 | 0 | 0 | 0.3 |
| Switzerland | 1 | 0 | 1 | 0 | 0 | 0.3 |
| Czech Republic | 1 | 1 | 0 | 0 | 0 | 0.2 |
| Finland | 1 | 1 | 0 | 0 | 0 | 0.2 |
| China | 2 | 0 | 2 | 0 | 0 | 0.1 |
| Organization | Organization type | Country | Publications | 1-10 auth | 11-50 auth | 51-200 auth | Over 200 auth | Publications (frac) |
|---|---|---|---|---|---|---|---|---|
| Uppsala University | University | Sweden | 42 | 25 | 16 | 1 | 0 | 7.7 |
| Technical University of Denmark (DTU) | University | Denmark | 15 | 7 | 7 | 1 | 0 | 3.1 |
| Karolinska Institutet | University | Sweden | 14 | 6 | 7 | 1 | 0 | 2.4 |
| AstraZeneca | Company | United Kingdom | 8 | 2 | 6 | 0 | 0 | 1.8 |
| Swedish University of Agricultural Sciences | University | Sweden | 6 | 6 | 0 | 0 | 0 | 1.5 |
| Lund University | University | Sweden | 9 | 3 | 6 | 0 | 0 | 1.3 |
| Indian Institutes of Technology | University | India | 4 | 4 | 0 | 0 | 0 | 1.2 |
| Affibody AB | Company | Sweden | 3 | 2 | 1 | 0 | 0 | 0.8 |
| Stockholm University | University | Sweden | 4 | 2 | 2 | 0 | 0 | 0.7 |
| Tomsk Polytechnic University | University | Russian Federation | 3 | 1 | 2 | 0 | 0 | 0.7 |
| Chalmers University of Technology | University | Sweden | 6 | 1 | 4 | 1 | 0 | 0.7 |
| Spiber Technology AB | NA | Sweden | 2 | 2 | 0 | 0 | 0 | 0.6 |
| AstraZeneca | Company | Sweden | 3 | 1 | 2 | 0 | 0 | 0.6 |
| RISE - Research Institutes of Sweden | Institute | Sweden | 2 | 2 | 0 | 0 | 0 | 0.6 |
| Albanova University Centre | University Other | Sweden | 4 | 3 | 1 | 0 | 0 | 0.6 |
| Russian Academy of Sciences | Other Public | Russian Federation | 2 | 0 | 2 | 0 | 0 | 0.5 |
| BAM Institute | Institute | Germany | 1 | 1 | 0 | 0 | 0 | 0.5 |
| Humboldt-Universität zu Berlin | University | Germany | 1 | 1 | 0 | 0 | 0 | 0.5 |
| University of Groningen | University | Netherlands | 3 | 1 | 2 | 0 | 0 | 0.5 |
| Kymab | NA | United Kingdom | 2 | 1 | 1 | 0 | 0 | 0.4 |
| Inventia AB | Institute | Sweden | 1 | 1 | 0 | 0 | 0 | 0.4 |
| Nanyang Technological University | University | Singapore | 1 | 1 | 0 | 0 | 0 | 0.4 |
| Linnaeus University | University | Sweden | 2 | 2 | 0 | 0 | 0 | 0.4 |
| ACIB Austrian Ctr Ind Biotechnol | NA | Austria | 1 | 0 | 1 | 0 | 0 | 0.4 |
| Sobi AB | Company | Sweden | 1 | 0 | 1 | 0 | 0 | 0.4 |
| University of Natural Resources and Life Sciences Vienna | University | Austria | 1 | 0 | 1 | 0 | 0 | 0.4 |
| BioGaia AB | Company | Sweden | 1 | 1 | 0 | 0 | 0 | 0.3 |
| University of Melbourne | University | Australia | 1 | 1 | 0 | 0 | 0 | 0.3 |
| University of Toronto | University | Canada | 1 | 1 | 0 | 0 | 0 | 0.3 |
| University of Gothenburg | University | Sweden | 4 | 0 | 3 | 1 | 0 | 0.3 |
| KEYW | Company | United States | 1 | 1 | 0 | 0 | 0 | 0.3 |
| SP Group | Company | Sweden | 1 | 1 | 0 | 0 | 0 | 0.3 |
| University of California, San Diego | University | United States | 1 | 1 | 0 | 0 | 0 | 0.3 |
| University of Paris-Sud 11 | University | France | 1 | 1 | 0 | 0 | 0 | 0.3 |
| US Naval Research Laboratory (NRL) | Other Public | United States | 1 | 1 | 0 | 0 | 0 | 0.3 |
| Erasmus MC | NA | Netherlands | 1 | 0 | 1 | 0 | 0 | 0.3 |
| Res Tomsk Polytech Univ | University | Russian Federation | 1 | 0 | 1 | 0 | 0 | 0.3 |
| ETH Zurich | University | Switzerland | 1 | 0 | 1 | 0 | 0 | 0.3 |
| Syncona Investment Ltd | Company | United Kingdom | 1 | 0 | 1 | 0 | 0 | 0.3 |
| AdBIOPRO Competence Ctr Adv BioProd Continuous P | NA | Sweden | 1 | 1 | 0 | 0 | 0 | 0.2 |
| Catholic University of Leuven | University | Belgium | 1 | 1 | 0 | 0 | 0 | 0.2 |
| Competence Ctr Adv Bioprod Continuous Proc | NA | Sweden | 1 | 0 | 1 | 0 | 0 | 0.2 |
| GammaDelta Therapeut Ltd | NA | United Kingdom | 1 | 0 | 1 | 0 | 0 | 0.2 |
| Hasselt University | University | Belgium | 1 | 1 | 0 | 0 | 0 | 0.2 |
| Palacky University | University | Czech Republic | 1 | 1 | 0 | 0 | 0 | 0.2 |
| Spiber AB | Company | Sweden | 1 | 1 | 0 | 0 | 0 | 0.2 |
| University of Antwerp | University | Belgium | 1 | 1 | 0 | 0 | 0 | 0.2 |
| Wallenberg Ctr Prot Res WCPR | NA | Sweden | 1 | 0 | 1 | 0 | 0 | 0.2 |
| University of Bergen | University | Norway | 4 | 0 | 4 | 0 | 0 | 0.2 |
| University of Texas Medical Branch at Galveston | University | United States | 4 | 0 | 4 | 0 | 0 | 0.2 |
| Atlas Antibodies AB | Company | Sweden | 2 | 0 | 2 | 0 | 0 | 0.2 |
| Ctr Adv Bioprod Continuous Proc AdBIOPRO | NA | Sweden | 1 | 1 | 0 | 0 | 0 | 0.2 |
| Free University of Brussels | University | Belgium | 1 | 1 | 0 | 0 | 0 | 0.2 |
| Immunovia AB | NA | Sweden | 1 | 1 | 0 | 0 | 0 | 0.2 |
| Korea Advanced Institute of Science and Technology | University | Korea, Republic of | 1 | 1 | 0 | 0 | 0 | 0.2 |
| VIB | Institute | Belgium | 1 | 1 | 0 | 0 | 0 | 0.2 |
| Aalto University | University | Finland | 1 | 1 | 0 | 0 | 0 | 0.2 |
| Karolinska University Hospital | University Hospital | Sweden | 1 | 1 | 0 | 0 | 0 | 0.2 |
| National Institute of Pharmaceutical Education and Research (NIPERs) | Institute | India | 1 | 1 | 0 | 0 | 0 | 0.2 |
| University of British Columbia | University | Canada | 1 | 1 | 0 | 0 | 0 | 0.2 |
| University of Maryland, Baltimore | University | United States | 1 | 1 | 0 | 0 | 0 | 0.2 |
| University of Tokyo | University | Japan | 1 | 1 | 0 | 0 | 0 | 0.2 |
| University of York | University | United Kingdom | 1 | 1 | 0 | 0 | 0 | 0.2 |
| VTT Technical Research Centre | Institute | Finland | 1 | 1 | 0 | 0 | 0 | 0.2 |
| West Bengal University of Animal and Fishery Sciences | University | India | 1 | 1 | 0 | 0 | 0 | 0.2 |
| University of Salamanca | University | Spain | 3 | 0 | 3 | 0 | 0 | 0.2 |
| Skåne University Hospital | University Hospital | Sweden | 3 | 0 | 3 | 0 | 0 | 0.2 |
| Sahlgrenska University Hospital | University Hospital | Sweden | 1 | 0 | 0 | 1 | 0 | 0.2 |
| Stanford University | University | United States | 1 | 0 | 0 | 1 | 0 | 0.2 |
| Barentzymes AS | Company | Norway | 1 | 1 | 0 | 0 | 0 | 0.1 |
| Swedish Orphan Biovitrum AB | Company | Sweden | 1 | 1 | 0 | 0 | 0 | 0.1 |
| Danderyds sjukhus | Other health services | Sweden | 1 | 0 | 1 | 0 | 0 | 0.1 |
| University Hospital North Norway | University Hospital | Norway | 1 | 0 | 1 | 0 | 0 | 0.1 |
| University of Tromsø | University | Norway | 1 | 0 | 1 | 0 | 0 | 0.1 |
| Clinnovo Research Labs | Company | India | 2 | 0 | 2 | 0 | 0 | 0.1 |
| FUDAN UNIVERSITY | University | China | 2 | 0 | 2 | 0 | 0 | 0.1 |
| Tokyo Medical and Dental University | University | Japan | 2 | 0 | 2 | 0 | 0 | 0.1 |
| Lab Surgpath | Other health services | India | 2 | 0 | 2 | 0 | 0 | 0.1 |
| Attana AB | Company | Sweden | 1 | 0 | 1 | 0 | 0 | 0.1 |
| Hosp GU Gregorio Maranon | Other health services | Spain | 1 | 1 | 0 | 0 | 0 | 0.1 |
| Max Planck Society for the Advancement of Science (MPG) | Institute | Germany | 1 | 1 | 0 | 0 | 0 | 0.1 |
| Univ Hosp Gregorio Maranon | University Hospital | Spain | 1 | 1 | 0 | 0 | 0 | 0.1 |
| Northwestern University | University | United States | 2 | 0 | 2 | 0 | 0 | 0.1 |
| University of Texas MD Anderson Cancer Center | Institute | United States | 2 | 0 | 2 | 0 | 0 | 0.1 |
| AbClon Inc | Company | Korea, Republic of | 1 | 0 | 1 | 0 | 0 | 0.1 |
| NimbleGen Systems GmbH | Company | Germany | 1 | 0 | 1 | 0 | 0 | 0.1 |
| Roche Holding AG | Company | United States | 1 | 0 | 1 | 0 | 0 | 0.1 |
| Seoul National University | University | Korea, Republic of | 1 | 0 | 1 | 0 | 0 | 0.1 |
| Dortmund University of Technology | University | Germany | 1 | 0 | 1 | 0 | 0 | 0.1 |
| University of Cambridge | University | United Kingdom | 1 | 0 | 1 | 0 | 0 | 0.1 |
| Cellutech | Company | Sweden | 1 | 0 | 1 | 0 | 0 | 0.1 |
| New York University | University | United States | 1 | 0 | 1 | 0 | 0 | 0.1 |
| Arizona State University | University | United States | 1 | 0 | 1 | 0 | 0 | 0.0 |
| Northeastern University | University | United States | 1 | 0 | 1 | 0 | 0 | 0.0 |
| University of California, Santa Cruz | University | United States | 1 | 0 | 1 | 0 | 0 | 0.0 |
| University of Michigan | University | United States | 1 | 0 | 1 | 0 | 0 | 0.0 |
| Yonsei University | University | Korea, Republic of | 1 | 0 | 1 | 0 | 0 | 0.0 |
| Publication Year | Publications | Open Access publications | OA gold | OA hybrid | OA green | OA bronze | Not OA | Share OA |
|---|---|---|---|---|---|---|---|---|
| 2014 | 13 | 6 | 1 | 3 | 2 | 0 | 7 | 46.2% |
| 2015 | 14 | 8 | 5 | 1 | 1 | 1 | 6 | 57.1% |
| 2016 | 12 | 4 | 2 | 1 | 0 | 1 | 8 | 33.3% |
| 2017 | 7 | 3 | 1 | 1 | 0 | 1 | 4 | 42.9% |
| 2018 | 17 | 8 | 1 | 3 | 3 | 1 | 9 | 47.1% |
| 2019 | 17 | 13 | 5 | 5 | 2 | 1 | 4 | 76.5% |
| 2020 | 19 | 18 | 10 | 7 | 1 | 0 | 1 | 94.7% |
| Total | 99 | 60 | 25 | 21 | 9 | 5 | 39 | 60.6% |
The Open Access type of the publications was fetched from the Unpaywall REST API. The method to determine the OA type is presented here.
In summary, the different OA types can be described as follows:
Gold: The full text has been found on a publisher website, in a journal that is fully OA.
Hybrid: The full text has been found on a publisher website, in a journal that is not fully OA.
Green: The full text has been found in an institutional repository, such as DiVA.
Bronze: The full text has been found on a publisher website but no OA license could be identified.
N.B.: This table is based on peer-reviewed publications for which Unpaywall could determine the OA type (necessary condition: have a DOI number). Unpaywall’s method is empirical and does not strictly equate to copyright license. As a consequence, the OA status of a given publication may vary with time — for example turning from “Not OA” to “Green” when a full text is added to DiVA.
| Publication Year | Publications | Total Citations | Average Citations | Uncited publications | Share uncited |
|---|---|---|---|---|---|
| 2014 | 2.1 | 63.4 | 30.3 | 0.3 | 15.9% |
| 2015 | 2.8 | 444.4 | 158.5 | 0.0 | 0.0% |
| 2016 | 3.5 | 48.5 | 14.0 | 0.0 | 0.0% |
| 2017 | 2.3 | 137.4 | 59.7 | 0.5 | 21.7% |
| 2018 | 4.9 | 39.4 | 8.0 | 0.4 | 8.1% |
| 2019 | 5.1 | 25.4 | 5.0 | 0.7 | 13.9% |
| 2020 | 5.3 | 21.7 | 4.1 | 1.8 | 33.0% |
| Total | 26.0 | 780.3 | 30.0 | 3.7 | 14.2% |
| Publication years | Publications | Average FWCI | Top 10% publications | Share Top 10% |
|---|---|---|---|---|
| 2014-2016 | 8.4 | 2.65 | 0.3 | 3.9% |
| 2015-2017 | 8.1 | 3.44 | 0.7 | 8.5% |
| 2016-2018 | 10.2 | 1.53 | 0.5 | 4.7% |
| 2017-2019 | 11.3 | 1.35 | 0.6 | 5.6% |
| Total | 19.6 | 1.91 | 1.0 | 4.9% |
This table is based on Scopus publication types Article, Review and Conference Paper.
Rows are based on at least 32 (full counted) publications with good Web of Science coverage (at least 79.9%).
(DiVA publication type Article, peer review)
Indicators based on < 50 publications are considered unreliable
| Publication years | Publications | Average SNIP | Publications in Top 20% journals | Share Top 20% journals |
|---|---|---|---|---|
| 2014-2016 | 8.4 | 1.31 | 3.2 | 38.3% |
| 2015-2017 | 8.1 | 1.59 | 4.4 | 54.1% |
| 2016-2018 | 10.2 | 1.60 | 6.6 | 64.5% |
| 2017-2019 | 11.8 | 1.65 | 8.8 | 74.5% |
| 2018-2020 | 14.7 | 1.54 | 9.0 | 61.0% |
| Total | 24.9 | 1.51 | 14.0 | 56.2% |
| Publication years | Publications | Corporate co-publications | Share corporate | International co-publications | Share international |
|---|---|---|---|---|---|
| 2014-2016 | 37 | 6 | 16.2% | 19 | 51.4% |
| 2015-2017 | 32 | 6 | 18.8% | 17 | 53.1% |
| 2016-2018 | 33 | 6 | 18.2% | 14 | 42.4% |
| 2017-2019 | 39 | 10 | 25.6% | 19 | 48.7% |
| 2018-2020 | 52 | 15 | 28.8% | 25 | 48.1% |
| Total | 97 | 22 | 22.7% | 48 | 49.5% |
This table is based on Scopus publication types Article, Review and Conference Paper.
Rows are based on at least 32 (full counted) publications with good Web of Science coverage (at least 90.2%).
(DiVA publication type Article, peer review)
Indicators based on < 50 publications are considered unreliable
